IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment
Pharmaceutics · 26.01.2025 · 17 (2) · 166
DOI: 10.3390/pharmaceutics17020166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.01.2025. Verfasst von Guangwei Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education), Minhang Hospital, Fudan University, Shanghai 201203, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Innovation Plan Laboratory Animal Research Project of Shanghai, National Natural Science Foundation of China, Excellent Young Medical and Pharmaceutical Talents Training Program of Health System of Shanghai Minhang District.
Abstract (Originalsprache)
Background
Photothermal therapy has the potential to enhance the precision and safety of oncological treatments. However, applicable photothermal agents associated with its photothermal activated immunogenic cell death remain exploiting.
Methods
This study evaluates the effectiveness of IR813, a photothermal agent, combined with near-infrared (NIR) light for cancer treatment. In vitro, 4T1 cancer cells were treated with IR813 (5 μg/mL) and exposed to NIR irradiation (1 W/cm2) for 5 min. In vivo, after the tumor-bearing mice administered with IR813 (1 mg/kg) and exposed to NIR irradiation (1 W/cm2) for 10 min, the tumor volume, survival and immune activation were evaluated.
Results
IR813 significantly increased the cytotoxicity of 4T1 cancer cells following near-infrared irradiation, resulting in the release of damage-associated molecular patterns and immunogenic cell death. Specifically, the cell viability was reduced to 5% compared to the control group. In vivo, irradiating the accumulation of IR813 at the tumor site had the potential to mediate substantial photothermal tumor suppression, improved mouse survival, and reduced metastasis, with minimal adverse reactions. Furthermore, the immune responses stimulated by IR813-induced photothermal therapy were evidenced by increased mature dendritic cell and cytotoxic T lymphocyte counts and a decrease in regulatory T cells in the spleen, tumor, and lymph nodes.
Conclusions
These findings suggest that IR813-induced photothermal therapy is a promising approach for enhancing immunotherapy, directly inhibiting tumors while boosting systemic anti-cancer immunity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education), Minhang Hospital, Fudan University, Shanghai 201203, China.
ORCID-Profile: Min Qian
Förderung
- Science and Technology Innovation Plan Laboratory Animal Research Project of Shanghai
- National Natural Science Foundation of China
- Excellent Young Medical and Pharmaceutical Talents Training Program of Health System of Shanghai Minhang District
Zitieren
APA
Jiang, G., Huang, R., Qian, M., Hu, W., & Huang, R. (2025). IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment. Pharmaceutics, 17(2), 166. https://doi.org/10.3390/pharmaceutics17020166
Vancouver
Jiang G, Huang R, Qian M, Hu W, Huang R. IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment. Pharmaceutics. 2025;17(2):166. doi:10.3390/pharmaceutics17020166
BibTeX
@article{Jiang2025,
author = {Jiang, Guangwei and Huang, Rong and Qian, Min and Hu, Wenjuan and Huang, Rongqin},
title = {IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {166},
doi = {10.3390/pharmaceutics17020166}
}
EUVIMED